Home › Companies › CULLINAN THERAPEUTICS INC. › 2023-2024
At CULLINAN THERAPEUTICS INC.'s shareholder meeting held June 26, 2024, in the 2023-2024 proxy season, 56 asset managers reported how they voted on 3 ballot items in their SEC Form N-PX filings, covering 506 separate fund positions. On the most widely held item on that ballot — Election of the following individuals nominated to serve as Class I directors, for a three-year… — FOR was 69% of the votes cast (FOR divided by FOR plus WITHHELD, because this ballot offered only for and withhold; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: CULLINAN THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 27, 2024.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and CULLINAN THERAPEUTICS INC.’s Form 8-K, filed June 27, 2024 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 26, 2024: 3 items on CULLINAN THERAPEUTICS INC.’s Form 8-K, filed June 27, 2024: 1 approved · 2 without a stated outcome.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore CULLINAN THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are CULLINAN THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 27, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Anne-Marie Martin, Ph.D. | 25,054,060 | -- | -- | 11,471,277 | 4,156,894 | 69% | Not verified | — |
| Elect Director: David Meek | 36,409,849 | -- | -- | 115,488 | 4,156,894 | 99.6% | Not verified | — |
| 2. Ratification of Appointment of Independent Registered Accounting Firm | 40,163,993 | 516,975 | 1,263 | -- | 0 | 99% | Approved | — |
Source: CULLINAN THERAPEUTICS INC., Form 8-K, filed with the SEC on June 27, 2024 — read the filing on EDGAR.
Each item below shows how the 56 asset managers that disclosed a CULLINAN THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
69% Majority: yes · of votes cast
Description as filed by funds: Election of the following individuals nominated to serve as Class I directors, for a three-year term ending at the annual meeting of stockholders to be held in 2027: Anne-Marie Martin, Ph.D.
CULLINAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: Anne-Marie Martin, Ph.D.”): 25,054,060 for, 11,471,277 withheld, per its Form 8-K filed June 27, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 69% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 56 asset managers below reported 3,793,386 for, 3,893,684 withheld, 52,686 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,765,852 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 1,424,151 | Withhold |
| BlackRock | 1,160,876 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 824,950 | Withhold |
| State Street | 864 | 0 | 0 | 793,954 | Withhold |
| Fidelity | 651,954 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 258,615 | Withhold |
| First Trust | 0 | 0 | 0 | 96,614 | Withhold |
| Equitable | 43,847 | 0 | 0 | 33,200 | Mixed |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 69,026 | Withhold |
| American Century | 0 | 0 | 0 | 63,159 | Withhold |
| TIAA | 0 | 0 | 0 | 62,247 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 48,195 | 0 | 0 | 0 | For |
| Invesco | 0 | 0 | 0 | 37,741 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 35,632 | Withhold |
| Nushares ETF Trust | 0 | 0 | 0 | 30,335 | Withhold |
| Nationwide | 479 | 0 | 0 | 21,478 | Withhold |
| Northern Trust | 21,882 | 0 | 0 | 0 | For |
| ProShares | 0 | 0 | 0 | 21,669 | Withhold |
| SEI | 0 | 0 | 0 | 19,639 | Withhold |
| T. Rowe Price | 17,051 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 0 | 0 | 0 | 15,433 | Withhold |
| ETF Series Solutions | 0 | 0 | 14,602 | 0 | Abstain |
| Exchange Place Advisors Trust | 0 | 0 | 14,240 | 0 | Abstain |
| Global X | 0 | 0 | 0 | 13,067 | Withhold |
Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99.6% Majority: yes · of votes cast
Description as filed by funds: Election of the following individuals nominated to serve as Class I directors, for a three-year term ending at the annual meeting of stockholders to be held in 2027: David Meek
CULLINAN THERAPEUTICS INC.’s own tally for this item (“Elect Director: David Meek”): 36,409,849 for, 115,488 withheld, per its Form 8-K filed June 27, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.6% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 56 asset managers below reported 7,739,756 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,765,852 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,424,151 | 0 | 0 | 0 | For |
| BlackRock | 1,160,876 | 0 | 0 | 0 | For |
| Dimensional | 824,950 | 0 | 0 | 0 | For |
| State Street | 794,818 | 0 | 0 | 0 | For |
| Fidelity | 651,954 | 0 | 0 | 0 | For |
| Charles Schwab | 258,615 | 0 | 0 | 0 | For |
| First Trust | 96,614 | 0 | 0 | 0 | For |
| Equitable | 77,047 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 69,026 | 0 | 0 | 0 | For |
| American Century | 63,159 | 0 | 0 | 0 | For |
| TIAA | 62,247 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 48,195 | 0 | 0 | 0 | For |
| Invesco | 37,741 | 0 | 0 | 0 | For |
| Lincoln Financial | 35,632 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 30,335 | 0 | 0 | 0 | For |
| Nationwide | 21,957 | 0 | 0 | 0 | For |
| Northern Trust | 21,882 | 0 | 0 | 0 | For |
| ProShares | 21,669 | 0 | 0 | 0 | For |
| SEI | 19,639 | 0 | 0 | 0 | For |
| T. Rowe Price | 17,051 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 15,433 | 0 | 0 | 0 | For |
| ETF Series Solutions | 14,602 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 14,240 | 0 | 0 | 0 | For |
| Global X | 13,067 | 0 | 0 | 0 | For |
Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).
Combines 3 wordings of this item as funds reported it.
99% Approved · of votes cast
Description as filed by funds: PROPOSAL TO RATIFY THE APPOINTMENT OF KPMG LLP AS CULLINAN THERAPEUTICS' INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2024.
CULLINAN THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Appointment of Independent Registered Accounting Firm”): 40,163,993 for, 516,975 against — passed, per its Form 8-K filed June 27, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal Two — Ratification of Appointment of Independent Registered Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2024 by the following votes:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 56 asset managers below reported 7,728,464 for, 11,292 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,765,852 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 1,424,151 | 0 | 0 | 0 | For |
| BlackRock | 1,160,876 | 0 | 0 | 0 | For |
| Dimensional | 824,950 | 0 | 0 | 0 | For |
| State Street | 794,504 | 314 | 0 | 0 | For |
| Fidelity | 651,954 | 0 | 0 | 0 | For |
| Charles Schwab | 258,615 | 0 | 0 | 0 | For |
| First Trust | 96,614 | 0 | 0 | 0 | For |
| Equitable | 77,047 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 69,026 | 0 | 0 | 0 | For |
| American Century | 63,159 | 0 | 0 | 0 | For |
| TIAA | 62,247 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 48,195 | 0 | 0 | 0 | For |
| Invesco | 37,741 | 0 | 0 | 0 | For |
| Lincoln Financial | 35,632 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 30,335 | 0 | 0 | 0 | For |
| Nationwide | 13,578 | 8,379 | 0 | 0 | Mixed |
| Northern Trust | 21,882 | 0 | 0 | 0 | For |
| ProShares | 21,669 | 0 | 0 | 0 | For |
| SEI | 19,639 | 0 | 0 | 0 | For |
| T. Rowe Price | 17,051 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 15,433 | 0 | 0 | 0 | For |
| ETF Series Solutions | 14,602 | 0 | 0 | 0 | For |
| Exchange Place Advisors Trust | 14,240 | 0 | 0 | 0 | For |
| Global X | 13,067 | 0 | 0 | 0 | For |
Showing the 25 largest of 56 asset managers. All 56 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 57,634,234 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.06% |
| 2 | FRANKLIN STRATEGIC SERIES | 2.47% |
| 3 | BlackRock | 2.01% |
| 4 | Dimensional | 1.43% |
| 5 | State Street | 1.38% |
| 6 | Fidelity | 1.13% |
| 7 | Charles Schwab | 0.45% |
| 8 | First Trust | 0.17% |
| 9 | Equitable | 0.13% |
| 10 | Direxion Shares ETF Trust | 0.12% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| UBS Oncology Impact Fund L.P. | 13.27% | DEF14A |
| Entities affiliated with BVF, Inc. | 10.16% | DEF14A |
| BlackRock | 7.24% | 13F |
| S | 5.70% | 13G |
| Entities affiliated with Franklin Resources, Inc. | 5.69% | DEF14A |
| Deerfield Partners, L.P. | 5.67% | DEF14A |
| Entities affiliated with Blue Owl Capital Holdings LP | 5.18% | DEF14A |
| Vanguard Group | 5.11% | 13F |
| Franklin Templeton | 4.68% | 13F |
| Franklin Resources, Inc. | 3.80% | 13G |
Percentages above are of 57,634,234 shares outstanding, as reported by CULLINAN THERAPEUTICS INC. on its Form 10-Q dated May 8, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CULLINAN THERAPEUTICS INC.’s 10-Q dated May 8, 2024. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
CULLINAN THERAPEUTICS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
proxyvotesnow.com, “CULLINAN THERAPEUTICS (CGEM) 2024 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/cullinan-therapeutics-inc/2024 (version of November 8, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.